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Abstract
Background: “Legal highs” are novel psychoactive substances that have evaded statutory control. Synthetic cannabinoid
compounds with adamantane moieties have recently been identified, which have high potency at target receptors and
are undetectable on conventional toxicology testing. However, little is known about any harmful effects, and their
potential to cause serious ill health. We describe a case of myocardial infarction following the use of this class of drug.
Case presentation: We report the case of a 39-year-old man admitted after an out-of-hospital cardiac arrest, in
whom ECG and elevated cardiac enzymes confirmed ST-elevation myocardial infarction. Normal coronary perfusion
was restored after thrombectomy and coronary artery stenting. In the hours preceding his admission, the patient is
known to have consumed the legal high product “Black Mamba”. Subsequent urine testing confirmed the presence of
an adamantyl-group synthetic cannabinoid, whilst cannabis, cocaine, amphetamines and other drugs of abuse were
not detected.
Conclusion: The use of legal highs is being increasingly recognised, but the chemical compositions and physiological
effects of these drugs are poorly characterised and are continually changing. Synthetic cannabinoids, rarely identified
on toxicological testing, can be linked to serious adverse cardiovascular events. This case highlights the importance of
testing for novel psychoactive compounds, and recognising their potential to cause life-threatening conditions.
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Background
Recreational use of cannabis dates back centuries. More
recently, herbal mixtures have emerged that produce
similar effects to cannabis when smoked. Sold under
various names, including Spice, K2 and Black Mamba,
these preparations can contain synthetically-derived
compounds with high affinity for endogenous cannabin-
oid CB receptors [1].
Novel psychoactive compounds are constantly being
developed and later prohibited in a cat-and-mouse game
between the legal high manufacturers and governments.
Synthetic cannabinoids represent an evolving drug class
that are sold openly (although frequently labelled “not
for human consumption”), produce stimulant effects in
those that smoke them, and are often undetectable on
routine toxicology testing.
However, because of their unregulated development,
synthetic cannabinoids can have potentially serious side
effects, putting those that use them at an unknown risk
of harm. Here, we report a case of myocardial infarction
and cardiac arrest associated with a new class of
adamantyl-group synthetic cannabinoid, confirmed by
urine drug testing.
Case presentation
A 39-year-old man presented to the emergency depart-
ment after a witnessed collapse and cardiac arrest. He
was Caucasian, with a body mass index of 28.8 kg/m2,
and a smoker. His past medical history consisted of de-
pression and a single episode of deep venous thrombosis
of the calf. There was no personal or family history of
cardiac disease, he was neither diabetic nor hypertensive,
and had a normal serum cholesterol level (2.5 mmol/l).
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Although he initially denied illicit drug use, a third party
confirmed he had smoked “Black Mamba” within three
hours of the onset of his symptoms.
He initially reported left-sided chest pain, associated with
dizziness and dyspnoea. Minutes later, the patient collapsed,
cardiac output became undetectable, and cardio-pulmonary
resuscitation was commenced. Out-of-hospital cardiac
monitoring revealed ventricular fibrillation, and spontan-
eous circulation was restored after delivery of four direct
current shocks. During transfer to hospital, ECG demon-
strated ST elevation in antero-lateral leads (Fig. 1), and the
patient was admitted directly for cardiac catheterisation.
The serum Troponin-T level was recorded at 4398 ng/L
(normal range <14 ng/L on high-sensitivity Troponin-T),
confirming the diagnosis of myocardial infarction.
Coronary angiography revealed an ostial occlusion to
the left anterior descending artery, which was treated by
thrombectomy. There was some residual stenosis, which
could have represented mild coronary artery disease or
persistent vasospasm. As it did not respond to nitrate
treatment, a Xience drug-eluting stent (Abbott) was
placed. The left circumflex and right coronary arteries
were angiographically normal, and there were only mild
irregularities in an intermediate artery. The patient expe-
rienced no further symptoms of cardiac ischemia, and
the ST elevation resolved after percutaneous coronary
intervention. He was discharged with anti-platelet ther-
apy (ticagrelor 90 mg twice daily for one year, aspirin
75 mg daily for life) and secondary prevention for coron-
ary artery disease (atorvastatin 80 mg daily, bisoprolol
2.5 mg daily and perindopril 2 mg daily).
Urine toxicology tested positive for opiates and benzo-
diazepines (both given on admission to hospital), and
also for adamantyl-group synthetic cannabinoids. Other
drugs of abuse were not detected, including cannabis,
cocaine and amphetamines. Drugs were assayed by li-
quid tandem mass spectrometry (UPLC-MS/MS), and
confirmed by time-of-flight mass spectroscopy.
Discussion
In England and Wales, cannabis is consistently the most
frequently used illegal drug [2]. Although relatively
uncommon, cannabis use is associated with a number of
serious cardiovascular conditions, including myocardial
infarction and stroke [3], with cases of both coronary ar-
tery thrombosis and vasospasm reported [4, 5]. Synthetic
cannabinoid use has been associated with admission to
hospital for a range of symptoms, including anxiety, seiz-
ure, vomiting, and chest pain [6, 7]. ECG changes are
rarely seen after synthetic cannabinoid use, but possible
mechanisms for increasing the risk of myocardial infarc-
tion include tachycardia, hypertension, and metabolic
disturbances such at hypokalaemia [8]. Although most
toxicities are classed as minor or moderate [9], more
synthetic cannabinoid users seek medical attention than
would be expected for cannabis [10]. The increased risk
of adverse reaction to synthetic cannabinoid, compared
to cannabis, could be due to higher potency at CB
receptors, or to uncharacterised interactions with other
endogenous targets. Moreover, with the diversity of
molecular moieties seen on synthetic cannabinoids, it is
possible that the different classes have distinct target
profiles.
Synthetic cannabinoid use has previously been associ-
ated with acute myocardial infarction, in both adults and
children [11–14]. However, in many of these reports, the
self-reported use of synthetic cannabinoid products is not
confirmed by biochemical testing, and some patients also
tested positive for cannabis. Here, we describe a patient
whose reported drug use was confirmed by urine toxicol-
ogy testing, which also ruled out use of cannabis and other
drugs of abuse. Animal studies have recorded physio-
logical effects of adamantyl-cannabinoids from one to six
hours after administration, and a human study found
metabolite excretion peaked five to seven hours after self-
administration and was still detectable up to 160 hours
later [15–17]. Although inhaling synthetic cannabinoids
results in unpredictable doses [17], the details of our case
are consistent with the known pharmacological properties
of these substances. Coronary angiography showed mild
residual irregularities after thrombectomy, and given a
personal history of deep venous thrombosis, it is pos-
sible that this patient was particularly vulnerable to a
cardiovascular event. However, his 10-year QRISK2
Fig. 1 The patient’s ECG, recorded en route to the emergency department, showing ST elevation in anterolateral leads
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score (ClinRisk Ltd.) was 2.6 %, therefore the major
contributor to this event is most likely the consumption
of the adamantyl-cannabinoid in the hours before his
presentation.
We report a case of acute myocardial infarction associ-
ated with use of an adamantyl-cannabinoid. Adamantane
moieties have recently been found in synthetic cannabin-
oid compounds, and they produce potent CB receptor
ligands [18]. The Clinical Biochemistry Department of
our NHS Trust, closely linked to the UK National
Poisons Information Service, continually screens samples
received for toxicology testing, as well as legal high sam-
ples seized by UK Trading Standards and from prisons.
Our testing has found that adamantyl-cannabinoids are
currently the most popular class of synthetic cannabin-
oid on sale in the UK, particularly AKB-48, 5 F-AKB-48
and STS-135. Our drugs of abuse screen, carried out on
urine samples, yields a positive result for adamantyl-
cannabinoids if any of these compounds are detected [19].
Most of the previous reports of acute myocardial in-
farction were associated with the JWH class of synthetic
cannabinoid. However, the trend in Europe has been
away from this older class of drug, likely in response to
its scheduling as illegal, towards more potent com-
pounds [9]. Consistent with this, our laboratory now
rarely detects JWH-class synthetic cannabinoids.
Importantly, the street name of the legal high does not
necessarily indicate which psychoactive compound is
present. A recent outbreak of neurotoxicity and cardio-
toxicity in the US was attributed to a synthetic canna-
binoid known locally as “Black Mamba” [20]. However,
the compound identified from these patients is chem-
ically distinct from the “Black Mamba” detected in our
patient, as it lacks the characteristic adamantane moiety.
It is noteworthy that the adamantyl-cannabinoid AKB-
48 has been scheduled as illegal in the US [21], whilst it
currently remains unscheduled in the UK. This reflects
the ongoing evolution of legal highs, driven by consumer
demand for the drugs and statutory bodies criminalising
their use.
Conclusions
The legal high market is buoyant and rapidly evolving.
Whilst many illegal and controlled pharmaceutical drugs
can be identified with toxicology testing, novel psychoactive
substances are often undetectable on routine testing. Their
prevalence is therefore likely to be under-reported, and
their precise chemical composition unknown. However,
use of synthetic cannabinoids exposes people to the risk
of serious harm, including acute myocardial infarction.
It is important to identify when patients have consumed
psychoactive substances, both to manage any complica-
tions that arise, and also to inform the wider public
health debate.
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